MX2009010989A - Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas. - Google Patents

Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.

Info

Publication number
MX2009010989A
MX2009010989A MX2009010989A MX2009010989A MX2009010989A MX 2009010989 A MX2009010989 A MX 2009010989A MX 2009010989 A MX2009010989 A MX 2009010989A MX 2009010989 A MX2009010989 A MX 2009010989A MX 2009010989 A MX2009010989 A MX 2009010989A
Authority
MX
Mexico
Prior art keywords
making
methods
same
pharmaceutical compositions
lyophilized pharmaceutical
Prior art date
Application number
MX2009010989A
Other languages
English (en)
Spanish (es)
Inventor
Claire Dulieu
Tam Nguyen
Steve L Durfee
Richard J Holl
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2009010989A publication Critical patent/MX2009010989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009010989A 2007-04-11 2008-04-11 Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas. MX2009010989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290443A EP1980240A1 (en) 2007-04-11 2007-04-11 Lyophilized pharmaceutical compositions and methods of making and using same
PCT/US2008/004755 WO2008127679A1 (en) 2007-04-11 2008-04-11 Lyophilized pharmaceutical compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2009010989A true MX2009010989A (es) 2009-10-29

Family

ID=38477086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010989A MX2009010989A (es) 2007-04-11 2008-04-11 Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.

Country Status (5)

Country Link
EP (2) EP1980240A1 (enExample)
JP (2) JP2010523678A (enExample)
CA (1) CA2683603A1 (enExample)
MX (1) MX2009010989A (enExample)
WO (1) WO2008127679A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359812A1 (en) * 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
CA2796567C (en) 2010-03-31 2016-07-12 Wockhardt Limited Composition comprising insulin and herbal oil for transdermal or transmucosal administration
GB201007290D0 (en) * 2010-04-30 2010-06-16 R5 Pharmaceuticals Ltd Pharmaceutical powder compositions
CN102440956B (zh) * 2011-12-21 2013-06-05 中国人民解放军第三军医大学 自乳化舒马曲坦及其盐制剂的制备方法
FR2987267B1 (fr) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma Application du modafinil dans le traitement de substitution des cacainomanes
GR20120100181A (el) * 2012-03-28 2013-10-15 Μαριαννα Αχιλλεα Παπαμιχαηλ Νεες λυοφιλοποιημενες φαρμακοτεχνικες και καλυντικοτεχνικες μορφες λυοφιλοποιημενων γαλακτωματων
CN104797239B (zh) * 2012-09-11 2018-09-21 约翰内斯堡威特沃特斯兰德大学 快速溶解药物组合物
HUE046869T2 (hu) 2014-11-21 2020-04-28 Biohaven Therapeutics Ltd Riluzol szublingvális formulációja
EP3368084A4 (en) * 2015-10-29 2019-07-03 Solubest Ltd PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL RELEASE
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
EP3923931A4 (en) * 2019-03-12 2022-10-26 Edenbridge Pharmaceuticals, LLC ORALLY DISINTEGRATING TABLETS COMPRISING GLYCOPYRROLATE AND METHODS FOR ENHANCING BIOAVAILABILITY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
WO2001039836A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US7846478B2 (en) * 2002-01-31 2010-12-07 Henkel Ag & Co. Kgaa Bioadhesive composition
JP2006512409A (ja) * 2002-10-31 2006-04-13 ユーエムディー， インコーポレイテッド 薬物送達用治療組成物で被覆上皮に対するもの及びそれを介するもの
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
WO2006103657A2 (en) * 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
JP5507840B2 (ja) * 2005-09-19 2014-05-28 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ 口腔粘膜医薬投与形態

Also Published As

Publication number Publication date
JP2015028030A (ja) 2015-02-12
WO2008127679A1 (en) 2008-10-23
CA2683603A1 (en) 2008-10-23
EP2152234A1 (en) 2010-02-17
JP2010523678A (ja) 2010-07-15
EP1980240A1 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
TW200621317A (en) Pharmaceutical composition
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
MY161595A (en) Oral care compositions
MX2011011486A (es) Composiciones orales que contienen compuestos de poliguandino y metodos de preparacion y uso de las mismas.
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12012501620A1 (en) Oral care compositions
TW200744624A (en) Lyophilized therapeutic peptibody formulations
ECSP066715A (enExample)
BR112012032882A2 (pt) liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides
PL1800669T3 (pl) Kompozycja farmaceutyczna, rozpraszalna w ustach, do podawania agomelatyny drogą ustną, przez błonę śluzową ust lub drogą podjęzykową
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
TN2009000447A1 (en) An extented-release composition comprising a somatostatin derivative in microparticles
MX2010009848A (es) Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
HUP0600809A2 (en) New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal